Navigation Links
A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center. [Ed : Her2/neu is a protein often present / surexpressed in breast cancer] Their study, published in the online journal, Breast Cancer Research, on Nov. 29, 2004, showed that the vaccine protected 86 percent of experimental mice against HER2/neu-associated breast cancer, even though the tumors were implanted directly into mice.

“This is an exciting strategy that seems to elicit a complete immunologic response against HER2/neu,?says the study’s lead author, Lawrence Lachman, Ph.D., a professor in the Department of Experimental Therapeutics. “Now that we have gone as far as we can in animal studies, I hope this agent might be tested clinically both to treat HER2/neu breast tumors, and to prevent them from spreading.?Up to one-third of human breast cancers are associated with over-expression of the HER2/neu cell surface receptor protein, which continuously “tells?the cancer cell to grow, this producing an aggressive disease that is difficult to stop. The drug Herceptin treats this kind of breast cancer by “plugging?these receptors with a monoclonal antibody, but this treatment “produces only a passive and transitory immune reaction,?Lachman said. “This vaccine, however, like many that treat microbial infections, appears to create a memory in the immune system that produces a lasting protective response.?The vaccine used in this study is a “viral-vectored?approach, in which a naturally occurring virus is re-engineered to be propagation defective but still able to function as a delivery system for proteins from the cancer cells that are to be targeted by the animal’s immune system. The basis for this new va ccine is an RNA virus called VEE, for Venezuelan equine encephalitis, which in its natural form can cause disease in horses. Researchers at AlphaVax, Inc., a privately held biotechnology company in Research Triangle Park, N.C., have deleted certain genes from the VEE virus, thereby making it impossible for the vector version of virus to reproduce itself, but still allowing the vector to express the target protein. For this study, the researchers inserted the gene for the HER2/neu protein in place of the deleted viral genes and then packaged the virus vector into virus-like replicon particles, referred to as “VRP-neu.?When these non-propagating particles are injected into an animal, the vector directs the animal’s cells to make thousands of copies of the HER2/neu growth protein, says Lachman. In addition, the VRP-neu preferentially homes to specialized immune system cells known as dendritic cells, and infects them. Inside, VRP-neu produces high levels of the HER2/neu protein, which the dendritic cells then display on the outside of their cell surface. This is, in fact, a neat trick, says Lachman, because the function of dendritic cells is to flag the immune system by presenting “antigen,?or pieces of a foreign invader, to activate an immune response. “So now, the same immune system cells that rev up the immune system are displaying HER2/neu proteins as antigens,?Lachman says. What results is a strong response against HER2/neu that incorporates all three arms of the immune system ¯ B cell, T cell and natural killer cells ¯ and which creates a long-lasting immune memory primed to attack breast cancer cells that are studded with HER2/neu proteins, he says. In the experiments, three groups of seven mice were treated with three injections of a vaccine. The “control?arm received a VRP vaccine that contained an influenza protein, and the other two groups received one of two different doses of the VRP-neu vaccine. Researchers then implanted a HER2/neu-positive tumor into mam mary tissue in the mice. All of the control mice developed breast cancer but only one mouse in each of the VRP-neu groups did. In short, 86 percent of mice that received the vaccine were protected against the cancer. The experiment was repeated numerous times with the same result, says Lachman. Researchers also worked with mice that were genetically engineered to over-express HER2/neu. These mice normally develop breast cancer in all ten of their mammary glands by the time there are 120 days old. In this experiment, they vaccinated the mice three times with VRP-neu, and “not a single mouse developed a tumor,?says Lachman. Lachman suggests the vaccine might prove helpful in keeping human HER2/neu tumors from metastasizing, or spreading, but adds that this notion must be tested in human clinical trials. Lachman believes that the vaccine will address two additional safety considerations “because it is built of RNA that cannot insert itself into the genome, and the possibility of autoimmunity to it appears to be low, because normal cells express very small amounts of the HER2/neu growth protein.?
'"/>

Source:


Related biology news :

1. Lipids get new comprehensive classification system
2. NIH launches comprehensive effort to explore cancer genomics
3. Amgen introduces comprehensive financial assistance programs for cancer patients
4. RNA map provides first comprehensive understanding of alternative splicing
5. LIAI completes worlds most comprehensive analysis on influenza virus data
6. Poplar trees redirect resources in response to simulated attack
7. Scientists solve structure of key protein in innate immune response
8. Harmful chemicals may reprogram gene response to estrogen
9. Mouse with designer liver has enhanced glucose tolerance, insulin response
10. A protein in the eye may prevent immune response and protect eyes from disease
11. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... a standard fume hood and a high-performance fume hood. Along with the advantages ... and applications for ductless vs. ducted hoods in the laboratory. , Attendees will ...
(Date:9/19/2017)... ... 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, ... book "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in ... an interest in the potential of stem cell therapy and a fast friendship was formed. ...
(Date:9/19/2017)... Pleasanton, Calif. and Washington, D.C. (PRWEB) , ... ... ... to delivering rapid care during an biological outbreak is about to be eliminated, ... When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical ... recipients of its 2017 Science Student Award. The scholarship program is dedicated to ... community service defray the costs of obtaining their science education. , Avomeen began ...
Breaking Biology Technology: